Reply to "A better interpretation of data regarding the opioid switching to methadone"

Haiying Ding; Yu Song; Wenxiu Xin; Jiao Sun; Like Zhong; Qinfei Zhou; Chaoneng He; Liyan Gong; Luo Fang

doi:10.1186/s12904-023-01162-z

Reply to "A better interpretation of data regarding the opioid switching to methadone"

BMC Palliat Care. 2023 Jun 7;22(1):66. doi: 10.1186/s12904-023-01162-z.

Authors

Haiying Ding¹, Yu Song¹, Wenxiu Xin¹, Jiao Sun¹, Like Zhong¹, Qinfei Zhou², Chaoneng He¹, Liyan Gong³, Luo Fang⁴

Affiliations

¹ Department of Pharmacy, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.
² Department of Rare Cancer & Head and Neck Medical Oncology, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.
³ Department of Rare Cancer & Head and Neck Medical Oncology, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China. 1413472557@qq.com.
⁴ Department of Pharmacy, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China. fangluo@zjcc.org.cn.

Abstract

In our article ?Methadone switching for refractory cancer pain' (BMC palliative care, 2022) we explore the efficacy, safety and economics of methadone in treatment of patients with refractory cancer pain in China. Professor Mercadante provided a better interpretation of data regarding the opioid switching to methadone in the Matters Arising. In this article, we answered the questions in Mercadante et al.'s comments one by one.

Keywords: Cancer pain; Methadone; Opioid switching or rotation; Palliative care.

Publication types

Letter

MeSH terms

Analgesics, Opioid / therapeutic use
Cancer Pain*
Dose-Response Relationship, Drug
Humans
Methadone / therapeutic use
Neoplasms*
Pain, Intractable* / chemically induced
Palliative Care

Substances

Methadone
Analgesics, Opioid